Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Hisamitsu’s Allergic Rhinitis Drug Delivers Positive PIII Data
July 27, 2016
- Astellas Kicks Off Japan PIII for Renal Anemia Drug Roxadustat
July 27, 2016
- Hisamitsu’s US Unit Noven Transfers Rights to 2 Products to Sebela
July 27, 2016
- Luvox/Depromel Filed for Pediatric Obsessive-Compulsive Disorder in Japan: AbbVie, Meiji
July 26, 2016
- Asahi Kasei Pharma Seeks Nod for Longer Treatment Period for Teribone
July 25, 2016
- Fujifilm “Considering” Acquisition of Takeda’s Chemical Unit: Official
July 22, 2016
- PD-L1 Antibody Atezolizumab in Japan PIII for 7 Indications: Chugai
July 22, 2016
- Chugai Scores Solid Half-Year Sales on Meds for Cancer, Bone and Joint Disease
July 22, 2016
- Kyowa Kirin Ups January-June Earnings Guidance
July 22, 2016
- Chugai Picks Galderma as Global Partner for Antibody Atopic Dermatitis Drug
July 22, 2016
- Maruho, Galderma Give Update on Their Comprehensive Collaboration
July 21, 2016
- Hiroki Kitamura Picked as New Yoshindo President
July 21, 2016
- 38% of Complete Response Patients Remained in Remission for 5-Plus Years: Adcetris PII
July 20, 2016
- US FDA OKs Once-Daily Belviq: Eisai
July 20, 2016
- FDA, EMA Accept Opdivo Filing for Head and Neck Cancer
July 20, 2016
- Bayer, Taisho Join Hands on Switch OTC Version of Claritin
July 19, 2016
- Daiichi Sankyo to Commercialize Amgen’s 9 Investigational Biosimilars Including Adalimumab in Japan
July 15, 2016
- AnGes MG, Osaka Univ. Team Up for Joint Research on Novel Drug Delivery System
July 15, 2016
- Takeda Launches Awareness Campaign for Inflammatory Bowel Disease in Europe, US
July 14, 2016
- Not Much Difference in Efficacy, Safety between 2 PCSK9 Inhibitors: Dr Teramoto of Teikyo University
July 14, 2016
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…